Rosangela Lattanzio
@hsr.it
Scopus Publications
- Scan Density Matters: Reproducibility of AI-Derived OCT Biomarkers in Diabetic Macular Edema
Massimiliano Cocuzza, Makan Ziafati, Rosangela Lattanzio, Edoardo Midena, Francesco Bandello, et al.
Translational Vision Science and Technology, 2026 - What Lies beneath Diabetic Macular Edema: Latent Phenotypic Clustering and Differential Treatment Responses to Intravitreal Therapies
Maria Vittoria Cicinelli, Beatrice Leonardo, Giacomo Maiucci, Giuliano Martino, Makan Ziafati, et al.
Ophthalmology Science, 2026 - Macular Edema Resistance in Retinal Vein Occlusion and the Protective Role of PAMM Subtypes
MARIA VITTORIA CICINELLI, ENRICO MARIA PEPE, BEATRICE TOMBOLINI, MARCO ROMANELLI, STEFANO ALBERTINI, et al.
American Journal of Ophthalmology, 2026 - Risk Analysis of Retinal Hemangioblastomas in Nonadvanced Stages of von Hippel–Lindau Syndrome Using Ultra-widefield Imaging: The ULTRA von Hippel–Lindau Study
Ophthalmology Science, 2025 - AI-Assisted OCT Clinical Phenotypes of Diabetic Macular Edema: A Large Cohort Clustering Study
Edoardo Midena, Marco Lupidi, Lisa Toto, Giuseppe Covello, Daniele Veritti, et al.
Journal of Clinical Medicine, 2025
Purpose: To characterize, using clustering analysis, the OCT morphological and clinical phenotypes of diabetic macular edema (DME) in a very large population (>2000 DME eyes) using standardized and validated OCT-based biomarkers. Methods: A cross-sectional study was conducted on OCT scans collected from 2355 eyes of 1688 patients with DME and performed during real-world clinical practice. OCT scans were automatically analyzed by a software able to automatically quantify OCT key biomarkers: intraretinal fluid (IRF), subretinal fluid (SRF), hyperreflective retinal foci (I-HRF), and external limiting membrane (ELM) and ellipsoid zone (EZ) interruption. Clustering analysis was performed using the above-mentioned biomarkers, including the distribution of IRF across the three ETDRS rings. Results: The overall population was predominantly composed of type 2 diabetes patients (89%), with a mean diabetes duration of 15.6 ± 10.7 years and mean best corrected visual acuity (BCVA) of 63 ± 18 ETDRS letters. Multivariate clustering identified four morphological phenotypes with distinct patterns of fluid distribution associated with different I-HRF counts, SRF volume, and percentages of ELM/EZ integrity (p < 0.0001). Conclusions: This large OCT analysis identified distinct morphological subtypes of DME, confirming the clinical relevance of key imaging biomarkers. The distribution and severity of DME features differ among clusters, supporting the importance of OCT-based phenotyping in tailoring treatment strategies and understanding disease evolution. - Central Bouquet Hemorrhages in Retinal Vein Occlusion: A Distinct Pathway to Macular Atrophy
Maria Vittoria Cicinelli, Enrico Maria Pepe, Prithvi Ramtohul, Beatrice Tombolini, Stefano Puligheddu, et al.
Investigative Ophthalmology Visual Science, 2025 - Lamina cribrosa perfusion density is reduced in eyes with central retinal vein occlusion
Matteo Menean, Lorenzo Bianco, Lida Perna, Gaia L’Abbate, Rosangela Lattanzio, et al.
Graefe S Archive for Clinical and Experimental Ophthalmology, 2025 - Diabetes-Driven Retinal Neurodegeneration: Its Role in the Pathogenesis of Diabetic Retinopathy
Ilaria Viganò, Silvia Galbiati, Emanuela Aragona, Daniela Gabellini, Rosangela Lattanzio, et al.
Biomedicines, 2025
Diabetic retinopathy is a complication of diabetes characterized by an extremely low rate of progression. It takes several years to move from the onset of diabetes, both type 1 and type 2, to the development of retinal microaneurysms, then leading to proliferative diabetic retinopathy and vision loss. The recent demonstration that retinal microaneurysms are preceded and, possibly, caused by a subclinical neurodegeneration mainly affecting the neurovascular unit has suggested, on one hand, the possible existence of a previously unknown early neurodegenerative stage of diabetic retinopathy and, on the other, that an early “neuroprotective” treatment could end up preventing the development of the microvascular stages. This review summarizes the present situation in the field and focuses on the prevention of diabetic retinopathy, which seems, for the first time, to be within reach. - Vascular chorioretinal disorders
Ultra Widefield Imaging of the Retina, 2025 - Management of treatment-naïve diabetic macular edema patients: Review of real-world clinical data
Francesco Boscia, Daniele Veritti, Cristiana Iaculli, Rosangela Lattanzio, Simona Freda, et al.
European Journal of Ophthalmology, 2024
The high prevalence of Diabetic macular edema (DME) is a real global health problem. Its complex pathophysiology involves different pathways. Over the last decade, the introduction of intravitreal treatments has dramatically changed the management and prognosis of DME. Among the different treatment options, inhibitors of vascular endothelial growth factor (anti-VEGF) and intravitreal steroids implants represent the first-line therapy of DME. We conducted a review of electronic databases to compile the available evidence about the clinical management of DME in a clinical setting, with a special focus on treatment-naïve patients. Anti-VEGF therapies represent a valuable option for treating DME patients. However, many patients do not respond properly to this treatment and, due to its administration regimen, many patients receive suboptimal treatment in real life. Current evidence demonstrated that in patients with DME, DEX-i improved significantly both anatomic and visual outcomes. Besides eyes with insufficient anti-VEGF respond or recalcitrant DME cases, DEX-i can be effectively and safely used in treatment-naïve DME patients as first line therapy. DEX-i may be considered first line therapy in different clinical scenarios, such as DME eyes with a greater inflammatory component, patients with cardiovascular events, vitrectomized eyes, or those requiring cataract surgery. In conclusion, there are still many points for improvement pending in the clinical management of the patient with DME. Since DME treatment must follow a patient-tailored approach, selecting the best therapeutic approach for each patient requires a good understanding of the pathophysiology of DME. - Real-world experience with fluocinolone acetonide intravitreal implant in patients with diabetic macular edema
Luigi Capone, Pietro Airaghi, Pasquale Aragona, Nicolò Castellino, Maria Vittoria Cicinelli, et al.
European Journal of Ophthalmology, 2024 - Clinical characteristics and multimodal imaging findings in unilateral frosted branch angiitis: A case report
Giorgio Lari, Marco Battista, Alessandro Marchese, Alessandro Bordato, Rosangela Lattanzio, et al.
Retinal Cases and Brief Reports, 2024 - Rate and Predictors of Misclassification of Active Diabetic Macular Edema as Detected by an Automated Retinal Image Analysis System
Lamberto La Franca, Carola Rutigliani, Lisa Checchin, Rosangela Lattanzio, Francesco Bandello, et al.
Ophthalmology and Therapy, 2024 - Assessing Diabetic Retinopathy Staging With AI: A Comparative Analysis Between Pseudocolor and LED Imaging
Maria Vittoria Cicinelli, Salvatore Gravina, Carola Rutigliani, Lisa Checchin, Lamberto La Franca, et al.
Translational Vision Science and Technology, 2024 - Validation of Esaso Classification of Diabetic Maculopathy
Giacomo Panozzo, Elia Franzolin, Diana Giannarelli, Giulia Dalla Mura, Rosa Longo, et al.
European Journal of Ophthalmology, 2024 - From diagnosis to prognosis: A paradigm shift for multimodal imaging in assessing diabetic macular edema
Aurelio Apuzzo, Salvatore Gravina, Giacomo Panozzo, Rosangela Lattanzio, Maria Vittoria Cicinelli, et al.
European Journal of Ophthalmology, 2024 - Rate and associations of inner retinal thinning in eyes with retinal vein occlusion and regressed macular oedema
Maria Vittoria Cicinelli, Lamberto La Franca, Alessandro Berni, Leonardo Bottazzi, Alessandro Rabiolo, et al.
Eye Basingstoke, 2024 - Imaging Biomarkers of Mesopic and Dark-Adapted Macular Functions in Eyes With Treatment-Naïve Mild Diabetic Retinopathy
Francesco Bandello, Enrico Borrelli, Marco Trevisi, Rosangela Lattanzio, Riccardo Sacconi, et al.
American Journal of Ophthalmology, 2023 - Associations and Prognostic Significance of Fluctuations in Diabetic Retinopathy Severity in Eyes Treated for Diabetic Macular Edema
Maria Vittoria Cicinelli, Giulia Gregori, Alessandro Rabiolo, Beatrice Tombolini, Costanza Barresi, et al.
Ophthalmologica, 2023 - Factors associated with the response to fluocinolone acetonide 0.19 mg in diabetic macular oedema evaluated as the area-under-the-curve
Maria Vittoria Cicinelli, Alessandro Rabiolo, Luigi Capone, Carlo Di Biase, Rosangela Lattanzio, et al.
Eye Basingstoke, 2023 - Foveal eversion patterns in diabetic macular edema
Alessandro Arrigo, Andrea Saladino, Emanuela Aragona, Alessia Amato, Luigi Capone, et al.
Scientific Reports, 2022 - Multidisciplinary management of patients diagnosed with von Hippel-Lindau disease: A practical review of the literature for clinicians
Alessandro Larcher, Federico Belladelli, Giuseppe Fallara, Isaline Rowe, Umberto Capitanio, et al.
Asian Journal of Urology, 2022 - The Narrative Medicine Approach in the Treatment of Diabetic Macular Edema: An Italian Experience
Edoardo Midena, Chiara Polo, Luisa Frizziero, Maria Giulia Marini, Rosangela Lattanzio, et al.
International Journal of Environmental Research and Public Health, 2022 - Epiretinal Membrane Peeling in Eyes with Retinal Vein Occlusion: Visual and Morphologic Outcomes
Maria Vittoria Cicinelli, Irini Chatziralli, Sara Touhami, Anissa Smaoui, Beatrice Tombolini, et al.
Ophthalmology and Therapy, 2022 - Assessment of Diabetic Choroidopathy Using Ultra-Widefield Optical Coherence Tomography
Nicolò Nicolini, Beatrice Tombolini, Costanza Barresi, Francesco Pignatelli, Rosangela Lattanzio, et al.
Translational Vision Science and Technology, 2022
